Answers are grounded in this paper and cite their sources.
Background Doravirine (DOR) is a second-generation non-nucleoside reverse transcriptase inhibitor characterized by a favorable efficacy, safety, and drug-drug interaction profile. Although clinical trials have demonstrated the effectiveness of the triple, standard DOR-containing regimen (DOR/lamivudine/tenofovir disoproxil fumarate) in treatment-naïve and treatment-experienced people living with HIV (PLWH), real-world evidence regarding long-term outcomes after switching to standard or alternative DOR-containing regimens remains limited. This study aimed to evaluate the virological, immunological, metabolic, and safety outcomes of standard and alternative DOR-based antiretroviral therapy in a real-life cohort of PLWH. Methods Retrospective observational study including treatment-experienced PLWH who initiated a standard or alternative DOR-containing regimen. Viro-immunological and metabolic parameters were collected at baseline and 12 and 24 months after treatment switch. The primary endpoint was to evaluate treatment efficacy in terms of virological suppression and tolerability of the regimens. Secondary endpoints included changes in lymphocyte subsets and lipid profile with cardiovascular risk parameters. Results A total of 164 PLWH were included. All DOR-based regimens maintained high rates of virological suppression, with no significant loss of efficacy. Immunological parameters remained generally stable, with increases in absolute CD127+ and CD45RA+ T-cell counts and a reduction in CD38+CD8+ T cells. A significant improvement in lipid profile was observed after switching to DOR-based therapy, with reductions in total and LDL cholesterol in PLWH exposed to DOR-regimens containing TDF and with a higher proportion of PLWH achieving their target LDL cholesterol levels. Renal function remained stable, with no relevant changes in estimated glomerular filtration rate or proteinuria. Treatment discontinuation due to adverse events was uncommon. Conclusions In this real-life cohort of treatment-experienced PLWH, DOR-based regimens demonstrated sustained virological efficacy and tolerability over two years of follow-up. Switching to DOR was associated with favorable metabolic outcomes, particularly regarding lipid profile, and renal safety even among those exposed to TDF. Longitudinal changes in selected T-cell subsets were observed in this treatment-experienced cohort. Overall, these findings support DOR as an option for treatment optimization in PLWH requiring long-term antiretroviral management.
No takes yet. Share an insight, caveat, or question.
Nardo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: